MolDX: EndoPredict Breast Cancer Gene Expression Test

This contractor provides limited coverage of the EndoPredict gene expression test for post-menopausal women with early-stage (T1-T3, N0-N1) ER-positive, HER2-negative breast cancer who are being considered for adjuvant endocrine therapy; the test identifies patients at low 10-year distant recurrence risk who may avoid chemotherapy. Coverage is restricted to the specific population described; use outside these criteria is not covered by this policy.

"EndoPredict is covered for post-menopausal women with early-stage breast cancer (TNM stage T1-T3, N0-N1) that is estrogen receptor (ER) positive and HER2-negative, who are node-negative or have 1-3..."

Sign up to see full coverage criteria, indications, and limitations.